Fluticasone chemical structure
Find information on thousands of medical conditions and prescription drugs.

Fluticasone

Fluticasone proprionate is a glucocorticoid often prescribed as treatment for asthma and allergic rhinitis. It is marketed with the brand name Flixotide® and Flixonase® by Allen & Hanburys and Flovent® and Flonase® by GlaxoSmithKline. more...

Home
Diseases
Medicines
A
B
C
D
E
F
Captagon
Famohexal
Famotidine
Faslodex
Faslodex
Fasoracetam
Felbamate
Felbatol
Felodipine
Felypressin
Femara
Femara
Fempatch
Femring
Fenfluramine
Fenofibrate
Fentanyl
Fexofenadine
Filgrastim
Filipin
Finasteride
Fioricet
Fiorinal
Flagyl
Flarex
Flavoxate
Flecainide
Flexeril
Flomax
Flonase
Flovent
Floxuridine
Fluacizine
Flucloxacillin
Fluconazole
Flucytosine
Fludarabine
Fludrocortisone
Flumazenil
Flunisolide
Flunitrazepam
Fluocinonide
Fluohexal
Fluorometholone
Fluorouracil
Fluoxetine
Fluphenazine
Flurazepam
Flutamide
Fluticasone
Fluvastatin
Fluvoxamine
FML
Focalin
Folic acid
Follutein
Fomepizole
Formoterol
Fortamet
Fortovase
Fosamax
Fosinopril
Fosinoprilat
Fosmidomycin
Fosphenytoin
Frova
Frovatriptan
Frusehexal
Fulvestrant
Fumagillin
Furazolidone
Furosemide
Furoxone
Fusafungine
Fusidic acid
Fuzeon
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

How it works

The precise mechanisms of glucocorticoid action in asthma are unknown. Inflammation is recognized as an important component in the pathogenesis of asthma. Glucocorticoids have been shown to inhibit multiple cell types (e.g., mast cells, eosinophils, basophils, lymphocytes, macrophages, and neutrophils) and mediator production or secretion (e.g., histamine, eicosanoids, leukotrienes, and cytokines) involved in the asthmatic response. These anti-inflammatory actions of glucocorticoids may contribute to their efficacy in asthma. Typically, however, the action on the cells affected requires several days. Therefore, inhaled steroids are not used for immediate relief of asthma, but instead as preventive and maintenance therapy.

Clinical trials

This listing is NOT complete and should NOT be construed as support for treatment decisions. See also PubMed clinical manuscripts referring to fluticasone

  • Burge, P.S.; Calverley, P.M.; Jones, P.W.; Spencer, S.; Anderson, J.A.; and Maslen T.K. (2000). Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. British Medical Journal 320 (7245), 1297-1303. PMID 10807619.
  • Paggiaro, P.L.; Dahle, R.; Bakran, I.; Frith, L.; Hollingworth, K.; and Efthimiou, J. (1998). Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. The Lancet 351 (9105), 773-780. PMID 9519948.
both support a positive outcome for use of fluticasone in patients with chronic obstructive pulmonary disease, also referred to as COPD

Read more at Wikipedia.org


[List your site here Free!]


Efficacy of inhaled fluticasone plus salmeterol in COPD
From American Family Physician, 5/1/04 by Karl E. Miller

Chronic obstructive pulmonary disease (COPD), which is characterized by airflow limitation that is not fully reversible, affects a significant portion of Americans and is the fourth leading cause of death in the United States. Current treatment guidelines recommend bronchodilators as first-line therapy. Depending on the disease severity, inhaled corticosteroids may be added. Multiple studies examining the use of inhaled corticosteroids in patients with COPD have shown that corticosteroids have a positive impact on short- and long-term clinical outcomes. In addition, one study found that inhaled corticosteroids reduced COPD-related morbidity and mortality in elderly patients. Inhaled salmeterol has proved effective in improving lung function, symptoms, and quality of life in patients with COPD. Hanania and associates evaluated the efficacy and safety of a combination of fluticasone propionate and salmeterol in patients with COPD.

The randomized, double-blind, placebo-controlled, parallel-group, multicenter trial enrolled patients who had a diagnosis of COPD as defined by the American Thoracic Society and who met spirometry parameters. After a two-week run-in, patients were randomized to receive 250 mcg of fluticasone, 50 mcg of salmeterol, a combination of both agents, or placebo delivered twice daily through a single device for 24 weeks. Treatment efficacy was assessed by measuring forced expiratory volume in one second (FE[V.sub.1]) before and two hours after medication use. Other measures assessed included morning peak expiratory flow (PEF), dyspnea symptoms, supplemental albuterol use, health status, symptoms of chronic bronchitis, and exacerbation of symptoms. Safety was evaluated by recording adverse events, electrocardiogram readings, vital signs, clinical laboratory tests, oropharyngeal examinations and, in some centers, results of a cosyntropin-stimulation test.

Compared with placebo or salmeterol alone, the combination of fluticasone and salmeterol significantly increased pre-dose FE[V.sub.1]. The combination treatment also significantly improved the two-hour post-dose FE[V.sub.1] compared with placebo and fluticasone alone. Lung function as measured by morning PEF improved with the fluticasone/salmeterol combination. Compared with placebo, the combination significantly improved dyspnea, quality of life, and symptoms of bronchitis. Adverse events were similar between the four treatment groups, except for oral candidiasis, which was higher in the combination and fluticasone-only groups.

The authors conclude that a combination of fluticasone and salmeterol twice daily substantially improves lung function in patients with COPD compared with either medication alone over a 24-week period. They note that the combination therapy does not increase adverse events compared with use of individual agents.

Hanania NA, et al. The efficacy and safety of fluticasone propionate (250 [micro]g)/salmeterol (50 [micro]g) combined in the Diskus inhaler for the treatment of COPD. Chest September 2003;124:834-43.

COPYRIGHT 2004 American Academy of Family Physicians
COPYRIGHT 2004 Gale Group

Return to Fluticasone
Home Contact Resources Exchange Links ebay